Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kissei Pharmaceutical Co ( (JP:4547) ) has provided an update.
Kissei Pharmaceutical has released supplementary explanatory materials on its financial results for the nine months ended December 31, 2025, including consolidated statements of income, trends in main product sales, and updates on both in-house and out-licensed R&D pipelines. The disclosure underscores the company’s continued emphasis on product sales performance and pipeline development as key drivers of its operations and future growth, while noting that its outlook is subject to business risks and uncertainties that may cause actual results to differ from current expectations.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4900.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange under stock code 4547, operating in the healthcare and life sciences industry with a focus on developing, manufacturing, and selling prescription drugs supported by in-house and out-licensed R&D pipelines.
Average Trading Volume: 66,884
Technical Sentiment Signal: Buy
Current Market Cap: Yen185B
See more data about 4547 stock on TipRanks’ Stock Analysis page.